{"id":"gnr-068","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL5840702","moleculeType":null,"molecularWeight":"539.95"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GNR-068 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin. By reducing glucose reabsorption, GNR-068 helps to improve glycemic control in patients with type 2 diabetes.","oneSentence":"GNR-068 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:06.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06488664","phase":"PHASE3","title":"An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO GENERIUM","startDate":"2023-07-25","conditions":"Plaque Psoriasis","enrollment":422},{"nctId":"NCT06481215","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-03-11","conditions":"Healthy Volunteers","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ustekinumab biosimilar"],"phase":"phase_3","status":"active","brandName":"GNR-068","genericName":"GNR-068","companyName":"AO GENERIUM","companyId":"ao-generium","modality":"Biologic","firstApprovalDate":"","aiSummary":"GNR-068 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}